SIPLIMU Trademark

Trademark Overview


On Tuesday, January 31, 2023, a trademark application was filed for SIPLIMU with the United States Patent and Trademark Office. The USPTO has given the SIPLIMU trademark a serial number of 97774867. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Wednesday, July 24, 2024. This trademark is owned by TEVA PHARMACEUTICALS USA, Inc.. The SIPLIMU trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations
siplimu

General Information


Serial Number97774867
Word MarkSIPLIMU
Filing DateTuesday, January 31, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateWednesday, July 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 5, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, February 17, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Friday, February 3, 2023NEW APPLICATION ENTERED
Friday, February 17, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, October 30, 2023ASSIGNED TO EXAMINER
Tuesday, October 31, 2023EXAMINERS AMENDMENT -WRITTEN
Tuesday, October 31, 2023EXAMINERS AMENDMENT E-MAILED
Tuesday, October 31, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, November 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 5, 2023PUBLISHED FOR OPPOSITION
Tuesday, December 5, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 30, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 31, 2023EXAMINER'S AMENDMENT ENTERED
Tuesday, October 31, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 24, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 24, 2024SOU EXTENSION 1 GRANTED
Wednesday, July 24, 2024SOU EXTENSION 1 FILED
Wednesday, July 24, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED